HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 288 filers reported holding HAEMONETICS CORP in Q4 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,029,912 | +61.5% | 167,782 | +53.5% | 0.01% | +62.5% |
| Q2 2023 | $9,304,610 | +3.0% | 109,286 | +0.1% | 0.01% | 0.0% |
| Q1 2023 | $9,033,983 | -5.3% | 109,172 | -10.0% | 0.01% | 0.0% |
| Q4 2022 | $9,544,178 | +15.3% | 121,350 | +8.5% | 0.01% | 0.0% |
| Q3 2022 | $8,278,000 | +44.2% | 111,823 | +27.0% | 0.01% | +60.0% |
| Q2 2022 | $5,739,000 | -3.2% | 88,048 | -6.1% | 0.01% | 0.0% |
| Q1 2022 | $5,928,000 | +17.4% | 93,764 | -1.5% | 0.01% | +66.7% |
| Q4 2021 | $5,050,000 | -38.3% | 95,220 | -17.9% | 0.00% | -50.0% |
| Q3 2021 | $8,188,000 | +6.8% | 116,000 | +0.8% | 0.01% | 0.0% |
| Q2 2021 | $7,667,000 | -44.8% | 115,052 | -8.0% | 0.01% | -45.5% |
| Q1 2021 | $13,877,000 | -3.8% | 125,008 | +2.9% | 0.01% | 0.0% |
| Q4 2020 | $14,426,000 | +45.0% | 121,483 | +6.6% | 0.01% | +22.2% |
| Q3 2020 | $9,948,000 | -0.7% | 114,013 | +2.0% | 0.01% | -10.0% |
| Q2 2020 | $10,014,000 | -11.4% | 111,818 | -1.4% | 0.01% | -28.6% |
| Q1 2020 | $11,299,000 | -18.3% | 113,377 | -5.8% | 0.01% | +7.7% |
| Q4 2019 | $13,835,000 | -12.9% | 120,408 | -4.4% | 0.01% | -18.8% |
| Q3 2019 | $15,886,000 | +55.5% | 125,937 | +48.3% | 0.02% | +33.3% |
| Q2 2019 | $10,219,000 | +49.5% | 84,919 | +8.7% | 0.01% | +50.0% |
| Q1 2019 | $6,837,000 | -13.5% | 78,158 | -1.0% | 0.01% | -27.3% |
| Q4 2018 | $7,900,000 | -13.6% | 78,958 | -1.0% | 0.01% | -8.3% |
| Q3 2018 | $9,141,000 | +20.6% | 79,781 | -5.6% | 0.01% | +20.0% |
| Q2 2018 | $7,577,000 | -3.4% | 84,492 | -21.2% | 0.01% | -9.1% |
| Q1 2018 | $7,844,000 | +37.8% | 107,214 | +9.4% | 0.01% | +37.5% |
| Q4 2017 | $5,694,000 | +26.2% | 98,035 | -2.5% | 0.01% | +14.3% |
| Q3 2017 | $4,512,000 | +24.1% | 100,558 | +9.2% | 0.01% | +16.7% |
| Q2 2017 | $3,637,000 | -8.1% | 92,100 | -5.5% | 0.01% | 0.0% |
| Q1 2017 | $3,956,000 | -6.1% | 97,500 | -7.0% | 0.01% | -14.3% |
| Q4 2016 | $4,213,000 | +16.1% | 104,800 | +4.6% | 0.01% | +16.7% |
| Q3 2016 | $3,628,000 | +21.9% | 100,200 | -2.4% | 0.01% | +20.0% |
| Q2 2016 | $2,977,000 | -13.6% | 102,700 | +4.3% | 0.01% | -16.7% |
| Q1 2016 | $3,446,000 | +12.2% | 98,500 | +3.4% | 0.01% | +20.0% |
| Q4 2015 | $3,072,000 | -7.7% | 95,300 | -7.5% | 0.01% | -16.7% |
| Q3 2015 | $3,329,000 | -18.5% | 103,000 | +4.3% | 0.01% | 0.0% |
| Q2 2015 | $4,086,000 | +11.0% | 98,800 | +1.2% | 0.01% | +20.0% |
| Q1 2015 | $3,680,000 | 0.0% | 97,600 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $3,680,000 | +7.1% | 97,600 | -0.8% | 0.01% | 0.0% |
| Q3 2014 | $3,436,000 | -1.3% | 98,398 | -0.3% | 0.01% | 0.0% |
| Q2 2014 | $3,482,000 | +5.4% | 98,698 | -3.9% | 0.01% | 0.0% |
| Q1 2014 | $3,304,000 | -22.4% | 102,698 | +3.5% | 0.01% | -16.7% |
| Q4 2013 | $4,257,000 | +9.7% | 99,198 | +1.9% | 0.01% | -14.3% |
| Q3 2013 | $3,882,000 | +27.0% | 97,334 | +31.6% | 0.01% | +16.7% |
| Q2 2013 | $3,057,000 | – | 73,934 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |